Answers are grounded in this paper and cite their sources.
In vitro and in vivo studies demonstrate enhanced oral bioavailability of AKBA, suggesting a new therapeutic platform.
These findings demonstrate that nanoemulsion-based delivery significantly improves the oral bioavailability of AKBA and provides a promising platform for its future therapeutic development.
No takes yet. Share an insight, caveat, or question.
Ketabchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: